Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Ups & SMEs

Set Alert for Start-Ups & SMEs

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.

BIO Financing

Syntis Bio Launches, Focusing On Oral Obesity Drugs And Rare Diseases

The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.

StartUps and SMEs Financing

Finance Watch: Two New VC Funds Bring $365m For Start-Ups

Private Company Edition: Amplitude Ventures raised $192m for its second fund, while XGEN Venture debuted with €160m ($173.4m). Also, hub-and-spoke biopharma operator CinRx added $73m, Adcendo extended its series A round to €98m ($106.2m) and Grey Wolf raised $50m.

Financing Innovation

Why Pheon Is Keeping Mum Over Target For Novel ADC

Intense competition in ADCs means Pheon is holding back details on its technology as it heads into Phase I studies after a $120m series B fundraising.

Companies Oncology

Mythic Therapeutics Faces An Acid Test

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.

Emerging Company Profile Biologics

Finance Watch: AltruBio, Pheon Raise Venture Capital Mega-Rounds

Private Company Edition: AltruBio raised up to $225m and Pheon garnered $120m in series B financings, while Lycia brought in $106.6m in series C cash. Also, Sands Capital closed its third life science fund, totaling $555m, and NewVale Capital debuted with $167m for life science services.

Financing Innovation

Alphabet To AI Connect, What Favors Drug Development At Indian Institutes Of Technology

After starring in India’s first CAR-T treatment, the country’s Indian Institutes of Technology, or IITs, are set to expand their drug development footprint. Scrip takes a look at what the Indian equivalents of the Massachusetts Institute of Technology have going for them, including sizeable funding and alumni like Alphabet's CEO.

Research & Development Business Strategies

Japan Looks For Role As Korean Ventures’ New Step To Global Market

Korean bioventures join an inaugural matching event with Japanese pharma firms at Shonan iPark, amid rising hopes for further bilateral partnerships based on respective R&D capabilities.

Japan South Korea

Ajax Set To ‘Attack JAK’ In Myelofibrosis With $95m In Series C Cash

Ajax Therapeutics plans to take its type II JAK2 inhibitor into the clinic during the second half of 2024 with the aim of modifying disease in a way that first-generation type I inhibitors do not. 

Financing Growth

Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Financing Immune Disorders

Zenas Raises $200m For Bifunctional Antibody In Autoimmune Diseases

Zenas BioPharma plans to have data from four trials – two under way and two starting this summer – for obexelimab, which targets CD19 and FcγRIIb, within about a year and a half.

Financing Immune Disorders

Finance Watch: Venture Rounds Trend Toward The High End

Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.

Financing Innovation
See All
UsernamePublicRestriction

Register